loading page

Idronoxil combined with cisplatin rescues refractory immune response in nasopharyngeal carcinoma
  • +7
  • Ngar-Woon Kam,
  • Desmond Tae-Yang Hung,
  • Man Kin Yim,
  • Ka Chun Wu,
  • Xin-Yuan Guan,
  • Olivier Laczka,
  • John Wilkinson,
  • Sai-Wah Tsao,
  • Victor Ho-Fun Lee,
  • Dora Kwong
Ngar-Woon Kam
University of Hong Kong
Author Profile
Desmond Tae-Yang Hung
University of Hong Kong
Author Profile
Man Kin Yim
University of Hong Kong
Author Profile
Ka Chun Wu
University of Hong Kong
Author Profile
Xin-Yuan Guan
University of Hong Kong
Author Profile
Olivier Laczka
Noxopharm Limited
Author Profile
John Wilkinson
Noxopharm Limited
Author Profile
Sai-Wah Tsao
The University of Hong Kong
Author Profile
Victor Ho-Fun Lee
University of Hong Kong
Author Profile
Dora Kwong
University of Hong Kong
Author Profile

Abstract

Background. Nasopharyngeal carcinoma is a chemosensitive cancer characterized by prominent lymphocytic infiltration. However, recurrence remains a major challenge in treating this disease. Here, we examined the effects of idronoxil (IDX) on tumor-lymphocyte interactions. Methods The antitumor activity of cisplatin and/or IDX was tested in authentic EBV-positive NPC-derived cell lines (C666, C17 and NPC43). We analyzed 2D monolayer and 3D spheroids cocultures of NPC cell lines with immune cells to assess the infiltration, activation, phenotype and function of T cells toward human nasopharyngeal tumors in vitro. Flow cytometric and immunohistochemical analyses were carried out to evaluate infiltrating T cells in subcutaneous mice models. Results. Administration of low-dose of IDX (1-2 µM) not only sensitizes cancer cells to chemotherapy via apoptosis, but also promotes T cell proliferation and cytotoxicity. More importantly, combination treatment of IDX and cisplatin in cancer cells can enhance the expansion, trafficking and priming of CD4+, CD8+ and double-positive (DP) T cells. Mechanistically, we showed that the increase in migratory DP T cells was largely mediated by the CXCL10/type I interferon (IFN) axis, where IDX precipitates an elevation in IFNα levels and leads to CXCL10 induction. Additionally, IDX enhanced T-cell infiltration towards tumor spheroids with acquisition of increased tissue homing and functional abilities (attenuated CD62L and PD1 expression). Conclusions. Our findings underscore the potential of IDX to induce immunomodulatory responses, and in combination with conventional chemotherapies, enhance antitumor immunity.